A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections
Latest Information Update: 04 Oct 2019
Price :
$35 *
At a glance
- Drugs Eravacycline (Primary) ; Ertapenem; Levofloxacin
- Indications Bacterial infections; Urinary tract infections
- Focus Registrational; Therapeutic Use
- Acronyms IGNITE3
- Sponsors Tetraphase Pharmaceuticals
- 13 Feb 2018 Status changed from active, no longer recruiting to completed, according to a Tetraphase Pharmaceuticals media release.
- 13 Feb 2018 Results presented in a Tetraphase Pharmaceuticals Media Release.
- 13 Feb 2018 According to a Tetraphase Pharmaceuticals media release, primary endpoint (Proportion of Participants in the micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) Visit)has not been met.